Cas:717904-43-3 4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid manufacturer & supplier

Chemical Name:4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid

CAS.NO:717904-43-3

Synonyms:MFCD04116817;4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-butyric acid

Molecular Formula:C₁₀H₁₈N₂O₄

Molecular Weight:230.26100

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:480.6ºC at 760 mmHg

Density:1.261g/cm3

Index of Refraction:1.53

PSA:81.08000

Exact Mass:230.12700

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD04116817 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-butyric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxo-butyric acid Use and application,MFCD04116817 technical grade,usp/ep/jp grade.

Related News: Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease. 4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid manufacturer Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities. 4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid supplier Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. 4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid vendor The Branchburg factory first came under FDA scrutiny in late 2019, when agency inspectors began to document numerous quality control problems. By March, 2020, the FDA had deemed the manufacturing issues as “Official Action Indicated,” its most serious category of violation. 4-[4-(2-hydroxyethyl)piperazin-1-yl]-4-oxobutanoic acid factory Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.